Acquisitions (Narrative) (Details)	3 Months Ended						0 Months Ended		3 Months Ended	0 Months Ended		2 Months Ended
	Mar. 31, 2014 USD ($)		Mar. 31, 2013 USD ($)		Feb. 28, 2014 USD ($)	Dec. 31, 2013 USD ($)	Feb. 28, 2014 Paladin Labs Inc. [Member] USD ($)	Feb. 28, 2014 Paladin Labs Inc. [Member] CAD	Mar. 31, 2014 Paladin Labs Inc. [Member] USD ($)	Feb. 03, 2014 Boca Pharmacal, LLC [Member] USD ($)	Feb. 28, 2014 Endo Health Solutions Inc. [Member]	Feb. 28, 2014 Five Year Senior Secured Term A Facility [Member]	Feb. 28, 2014 Five Year Senior Secured Term B Facility [Member]	Feb. 28, 2014 Five Year Revolving Credit Facility [Member] USD ($)	Feb. 28, 2014 Letter of Credit [Member] USD ($)	Feb. 28, 2014 Swing Line Loan [Member] USD ($)
Business Acquisition [Line Items]
Aggregate consideration transferred							$ 2,866,926,000
Number of New Endo shares Issued per share of Paladin Labs (shares)							1.6331	1.6331
Number of New Endo shares issued of Paladin Labs (shares)							35,500,000.0	35,500,000.0
Cash payment issued per share of acquired entity (cd per share)							$ 1.09	1.16
Number of New Endo shares issued per share of Endo (shares)							1	1			1
Equity interest in combined entity (percent)							21.00%	21.00%			79.00%
Debt instrument, term												5 years	7 years	5 years
Current borrowing capacity of line of credit facility														750,000,000	50,000,000	50,000,000
Maximum borrowing capacity of line of credit facility					75,000,000
Asset impairment charges	0		1,100,000
Goodwill impairment charges	0
Deferred tax liabilities							160,620,000
Acquisition-related and integration items	45,269,000	[1]	558,000	[1]					36,846,000
Transaction costs									33,400,000
Payments to acquire business										232,700,000
Total identifiable assets							1,142,830,000			221,800,000
Goodwill	$ 3,522,651,000					$ 1,372,832,000	$ 2,134,565,000			$ 10,800,000

[1] Acquisition-related and integration-items include costs directly associated with the closing of certain acquisitions, changes in the fair value of contingent consideration and the costs of integration activities related to both current and prior period acquisitions.